Author: Bella Hayes

Eagle Point Credit Management LLC and Eagle Point DIF GP I LLC, both significant shareholders in ACRES Commercial Realty Corp. (NYSE:ACR), recently filed a report indicating a series of stock sales. These transactions, which took place on December 17 and 18, involved the sale of preferred stock in the company, totaling $304,748. The sales come as ACR, currently valued at $110 million, has demonstrated strong performance with a 64% gain year-to-date, according to InvestingPro data. The sales included 2,965 shares of 7.875% Series D Preferred Stock at approximately $23.10 per share and 2,677 shares of 8.625% Series C Preferred Stock…

Global Medical REIT Inc (NYSE:) stock has reached a 52-week low, trading at $7.98, as investors navigate through a landscape of economic uncertainties. According to InvestingPro data, the stock’s RSI indicates oversold territory, while offering an attractive 10.3% dividend yield. The company maintains strong liquidity with a current ratio of 2.09. This new low comes as a significant downturn for the company, reflecting a 1-year change with a decline of -27.59%. The real estate investment trust, specializing in healthcare facilities, has faced headwinds that have affected its market performance, leading to this notable dip in its stock price. Investors are…

Company announcement “ No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concluded that Zealand Pharma (NASDAQ:)’s application did not meet the full requirements for substantial evidence to establish the efficacy and safety of the to-be-marketed dose of glepaglutide.Zealand Pharma will continue the dialogue with the FDA to align on the path toward obtaining regulatory approval in the U.S.Zealand Pharma expects to proceed with its current plans for a European Marketing Authorization Application submission in 2025. Copenhagen, Denmark, December 19, 2024…

Ellen A. Rudnick, a director at Old National Bancorp (NASDAQ:), recently made several stock acquisitions, according to the latest SEC filings. Over a series of transactions, Rudnick purchased a total of 64 shares of common stock, amounting to approximately $901. The acquisition prices ranged from $13.64 to $17.23 per share. The banking institution, currently valued at $7.1 billion, has demonstrated strong market performance with a 33% price return over the past six months. InvestingPro data reveals the company maintains an impressive 42-year streak of consecutive dividend payments, currently yielding 2.64%. These transactions, reported later than usual due to a communication…

Thursday’s trading session is witnessing notable movements in stocks across the board, particularly in the mega-cap and large-cap categories. Some stocks are experiencing significant gains post-earnings announcements, while others are facing sharp declines due to various factors. Here’s a look at some of the most significant movers in today’s market, from the largest companies by market cap to smaller firms making waves. Mega-Cap Movers (Market Cap $200B+): Accenture Ltd (NYSE:): Accenture Reports First-Quarter Fiscal 2025 Results; +7.48% Nvidia Corp (NASDAQ:): +3.01% Oracle Corp (NYSE:): +3.15% Large-Cap Stock Movers (Market Cap $10B-$200B):Darden Restaurants (NYSE:): Darden Restaurants Reports Fiscal 2025 Second Quarter…

RADNOR, Pa. – (NewMediaWire) – December 19, 2024 – The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against PACS Group, Inc. (PACS) (NYSE: PACS). The lawsuit is brought on behalf of investors who purchased or otherwise acquired PACS: 1) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the Registration Statement) issued in connection with PACS April 11, 2024 initial public offering (the IPO); and/or 2) securities between April 11, 2024 and November 5, 2024 inclusive (the Class Period). The lead plaintiff deadline…

In a challenging market environment, GT BioPharma Inc. (GTBP) stock has touched a 52-week low, reaching a price level of $1.92 . This significant downturn reflects a broader trend for the biopharmaceutical company, which has seen its stock price plummet over the past year. With a current market capitalization of just $4.47 million, the company’s shares have declined more than 73% year-to-date. InvestingPro analysis suggests the stock is currently trading below its Fair Value. The 1-year change data for Oxis International Inc, which is now known as GT BioPharma Inc., underscores the extent of the decline, with the company’s stock…

Herbalife (NYSE:) Nutrition Ltd. shares have tumbled to a 52-week low, with the stock price touching $6.58, reflecting a stark downturn in the company’s market performance. According to InvestingPro data, the company now carries a market capitalization of $671 million, with a notably low P/E ratio of 7.84, suggesting potential undervaluation relative to peers. Over the past year, the health and wellness brand has seen its stock value erode by a significant 55.58%, as investors reacted to a series of challenges that have beset the company. This latest price level underscores the difficulties Herbalife faces as it navigates a competitive…

Lear (NYSE:) Corporation’s stock has faced significant headwinds, touching a 52-week low of $92.1. According to InvestingPro analysis, the stock appears undervalued at these levels, with analyst price targets ranging from $99 to $174. The automotive technology leader, known for its seating and electrical systems, has seen its shares struggle in a challenging market environment, reflecting broader industry trends and economic pressures. Over the past year, Lear’s stock has experienced a substantial decline, with a 1-year change showing a decrease of 32.7%. Despite trading at an attractive P/E ratio of 9.75x and offering a 3.31% dividend yield, which has been…

LONDON – Dunedin Enterprise Investment Trust PLC has updated its timetable regarding the proposed members’ voluntary liquidation, as per its announcement on December 19, 2024. The trust has provided a revised schedule for its liquidation process and the suspension of its shares from the London Stock Exchange (LON:), pending approval from shareholders. According to the updated timetable, the last day for dealing in the company’s shares through CREST, on a normal rolling two-day settlement basis, is set for December 30, 2024. Shareholders must submit their Forms of Proxy by 10 a.m. on January 2, 2025, in advance of the general…